Keros Therapeutics (KROS) Revenue & Revenue Breakdown
Keros Therapeutics Revenue Highlights
Latest Revenue (Y)
$3.55M
Latest Revenue (Q)
$3.04M
Main Segment (Y)
License
Keros Therapeutics Revenue by Period
Keros Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $3.55M | 2250.99% |
2023-12-31 | $151.00K | 100.00% |
2022-12-31 | - | -100.00% |
2021-12-31 | $20.10M | 100.00% |
2020-12-31 | - | -100.00% |
2019-12-31 | $10.00M | - |
2018-12-31 | $10.00M | - |
Keros Therapeutics generated $3.55M in revenue during NA 2024, up 2250.99% compared to the previous quarter, and up 35.50% compared to the same period a year ago.
Keros Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-12-31 | $3.04M | 684.02% |
2024-09-30 | $388.00K | 948.65% |
2024-06-30 | $37.00K | -55.42% |
2024-03-31 | $83.00K | -41.96% |
2023-12-31 | $143.00K | 1687.50% |
2023-09-30 | $8.00K | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | -100.00% |
2022-06-30 | $100.00K | 100.00% |
2022-03-31 | - | -100.00% |
2021-12-31 | $20.00M | 100.00% |
2021-09-30 | - | -100.00% |
2021-06-30 | $100.00K | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | -100.00% |
2019-12-31 | $2.50M | - |
2019-09-30 | $2.50M | - |
2019-06-30 | $2.50M | - |
2019-03-31 | $2.50M | - |
Keros Therapeutics generated $3.04M in revenue during Q4 2024, up 684.02% compared to the previous quarter, and up 38025.00% compared to the same period a year ago.
Keros Therapeutics Revenue Breakdown
Keros Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 24 | Dec 22 | Dec 21 |
---|---|---|---|
Service | $3.00M | - | - |
License | $144.00M | $144.00M | $144.00M |
Latest
Keros Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (97.96%), and Service (2.04%).
Quarterly Revenue by Product
Product/Service | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
---|---|---|---|---|---|---|---|---|---|---|---|
Service, Other | $15.89M | $83.00K | - | - | - | - | - | - | - | - | - |
License | $195.35M | $144.00M | $144.00M | $144.00M | $144.00M | $18.00M | $20.00M | $100.00K | - | - | - |
Service | - | $2.60M | $400.00K | - | - | - | - | - | - | - | - |
Latest
Keros Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: License (92.48%), and Service, Other (7.52%).
Keros Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HRMY | Harmony Biosciences | $714.73M | $184.73M |
ANAB | AnaptysBio | $91.28M | $43.11M |
GLUE | Monte Rosa Therapeutics | $75.62M | $60.65M |
FENC | Fennec Pharmaceuticals | $47.54M | $7.92M |
MGTX | MeiraGTx | $33.28M | - |
SNDX | Syndax Pharmaceuticals | $23.68M | $20.04M |
SRZN | Surrozen | $10.65M | $655.00K |
JANX | Janux Therapeutics | $10.59M | - |
BOLT | Bolt Biotherapeutics | $7.69M | $1.22M |
IDYA | IDEAYA Biosciences | $7.00M | $7.00M |
IPSC | Century Therapeutics | $6.59M | $109.16M |
KROS | Keros Therapeutics | $3.55M | $3.04M |
EWTX | Edgewise Therapeutics | - | - |
REPL | Replimune Group | - | - |
AVTE | Aerovate Therapeutics | - | - |
KZR | Kezar Life Sciences | - | - |
MLYS | Mineralys Therapeutics | - | - |
ERAS | Erasca | - | - |
LRMR | Larimar Therapeutics | - | - |